Last reviewed · How we verify
NCT05704686
Clinical Outcomes of an New EDOF IOL (Isopure®)
trial testing Isopure 1.2.3 intraocular EDOF lens implantation in Lens Opacities in 62 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Kristof Vandekerckhove, MD, MBA |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 26 April 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Isopure 1.2.3 intraocular EDOF lens implantation
Conditions studied
- Lens Opacities — all drugs for Lens Opacities →
- Cataract — all drugs for Cataract →
- Pseudophakia — all drugs for Pseudophakia →
Sponsor
Kristof Vandekerckhove, MD, MBA
Who can join
50 and older, any sex, with Lens Opacities or Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single-center, retrospective, open-label observational study aiming to evaluate visual outcomes and patient satisfaction after bilateral implantation of Isopure® EDOF-IOL with a mono-minovision target.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05704686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lens Opacities
Currently open trials in the same condition.
- NCT06294405 — Intraocular Lens Implant Registry Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05704686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kristof Vandekerckhove, MD, MBA
- Last refreshed: 30 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05704686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing